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The investigation of the differentiation of terminal effectorCD8+CD57+T cells (TTE) in multiple 
myeloma (MM) and its premalignant stage, monoclonal gammopathy of undetermined significance 
(MGUS), is essential for understanding myeloma immune escape. We have previously shown that 
patients with clonal expansions of cytotoxic TTE cells have better outcomes than those who do not, but 
have not examined the underlining differentiation of TTE cells that leads to these distinct states. We 
hypothesised that a lack of clonally expanded TTE cells in myeloma patients could be due to myeloma 
induced alterations of TTE cell differentiation. To define TTE cell differentiation at high resolution, we 
have analysed paired bone marrow (BM) and peripheral blood (PB) samples from patients with newly 
diagnosed Myeloma (NDMM) and MGUS using time of flight mass cytometry and unsupervised 
clustering algorithm Flow Self-organizing Map (FlowSOM). We designed a 39 antibody panel, including 
antibodies to TCR-Vb families custom-labelled with heavy metals, allowing the detailed characterization 
of the phenotype of clonally expanded TTE cells. We found that in contrast to TTE cells in MGUS, TTE 
cells in BM of NDMM failed to display the phenotype typical of terminal effector cell differentiation 
and were enriched in atypical tissue resident CD69+, CD28+ and CD27+ subsets. They also failed to 
display the expected upregulation ofCD45RA and downregulation of CD45RO expression. Moreover, 
the accumulation of atypical CD69+ TTE cells was prevalent in myeloma patients without clonally 
expanded TTE cells. FlowSOM clustering discovered 4 metaclusters (MC) contributing to the 
accumulation of CD69+ TTE cells in the BM of NDMM patients. Phenotypically, two MC were in the 
memory stage based on CD27, CD28 and CD45RO expression and another two MC showed evidence 
of progression to the effector stage by downregulating CD27, CD28, CD45RO and upregulating 
CD45RA expression. Progression to the effector stage was associated with downregulation of CD38 and 
PD-1 expression, but did not affect persistent TIGIT expression. Vb expanded TTE cells did not 
contribute to the accumulation of CD69+ TTE cells and occupied phenotypically different MC with low 
or undetectable CD69 expression. When comparing phenotype of Vb expanded TTE cells to remaining 
TTE cells, effector and memory CD8+T cells they had higher Tbet, Perforin, Granzyme B, and lower 
levels of Eomes, TIGIT and PD-1 expression arguing against their exhaustion stage and confirming our 
previous observations that they resemble senescent cells. Our results suggest that accumulation of 
atypical tissue resident CD69+ TTE cells in myeloma infiltrated BM could prevent differentiation and 
expansion of clonal myeloma specific CD8+TTE cells and ultimately contribute to myeloma immune 
escape.  
